Skip to main content
Fig. 1 | Journal of Hematology & Oncology

Fig. 1

From: Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

Fig. 1

Adverse effects for which a frequency difference of ≥ 10% was observed between Asian and non-Asian populations in COMPARZ. ALT, alanine aminotransferase; AST, aspartate aminotransferase; LDH, lactate dehydrogenase; Paz, pazopanib; PPE, palmar-plantar erythrodysesthesia; Sun, sunitinib; WBC, white blood cells

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us